China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the National Medical Products Administration (NMPA) to initiate clinical trials for its JS212, a bispecific antibody drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). This marks a significant step forward in the development of innovative therapies for advanced solid tumors.
Drug Mechanism and Innovation
JS212 is designed to bind to EGFR or HER3, exerting tumor suppressive effects and overcoming drug resistance issues. This mechanism allows the drug to be effective against a wider range of tumors, addressing significant unmet medical needs in oncology.
Preclinical Success
The drug has demonstrated significant anti-tumor effects in multiple animal models during preclinical studies, with good and acceptable safety profiles. These promising results pave the way for its clinical evaluation in patients with advanced solid tumors.-Fineline Info & Tech
Leave a Reply